Featured conditions Brain tumor, breast cancer, colon cancer, congenital heart disease, heart arrhythmia. See more conditions.
Featured conditions
Results filtered:Study status: Open Closed for Enrollment
The purpose of this study is to assess the safety and effectiveness of the AltaValve System for the treatment of MR in targeted patient population.
The purpose of this early feasibility study (EFS) is to evaluate the safety and clinical performance of the VDyne System in the treatment of symptomatic severe tricuspid valve regurgitation (TR) in candidates suitable for transcatheter valve replacement. The study will provide information to allow for potential modifications to the VDyne System design or future study protocol, prior to initiating a pivotal study.
The purpose of this study is to assess the safety and technical feasibility of the Laplace Transcatheter Tricuspid Valve Replacement (TTVR) System.
The purpose of this study is to establish the safety and effectiveness of the SAPIEN M3 System in subjects with mitral regurgitation (MR) who are at high surgical risk.
The purpose of this study is to assess the technical and procedural success of the Innovalve TMVR system when used to treat adult patients with symptomatic moderate-severe and severe mitral regurgitation who are at elevated risk for surgical mitral valve repair or replacement and who are anatomically eligible for a transfemoral catheterization with transseptal approach to the left atrium.
To provide additional information about the safety and efficacy of the WATCHMAN LAA Closure Technology.
The aim of this study is to determine that percutaneous repair of paravavular defect has improved clinical outcomes, survival, reduced the incidence of hemolysis related to the paravalvular leak, and that percutaneous intervention has reduced the overall need for surgical intervention.
The purpose of this study is to identify novel genetic variants associated with stent thrombosis.
The purpose of this study is to demonstrate the safety and effectiveness of the AVP III as a treatment for clinically significant PVLs following surgical implant of a mechanical or biological heart valve implanted in the aortic or mitral position.
The purpose of this study is to assess the safety and performance of the Caisson Interventional Transcatheter MitralValve Replacement (TMVR) system for the treatment of severe symptomatic MitralValve Regurgitation (MR).